Sumitomo Dainippon Pharma Co Ltd is a Japanese company that values innovation, integrity, and dedication to improving patient outcomes. The company's corporate philosophy is rooted in contributing to society through the discovery and development of innovative pharmaceuticals. Sumitomo Dainippon Pharma Co Ltd focuses on research and development to provide effective and safe medical solutions to patients worldwide. With a commitment to continuous growth and improvement, the company strives to enhance the quality of life for individuals and the community as a whole. Sumitomo Dainippon Pharma Co Ltd's corporate philosophy guides its mission to contribute to the health and well-being of society by delivering innovative and reliable pharmaceutical products.

Sumitomo Dainippon Pharma Co Ltd is primarily present in Japan.

Sumitomo Dainippon Pharma Co Ltd has achieved several significant milestones throughout its history. Notably, the company successfully developed and launched innovative psychiatric medications, such as LATUDA, which has contributed to the treatment of schizophrenia and bipolar disorder. Additionally, Sumitomo Dainippon Pharma Co Ltd expanded its global presence through strategic partnerships and acquisitions, enhancing its research and development capabilities. The company's dedication to advancing healthcare is evident in its commitment to exploring breakthrough therapies and collaborations with leading medical institutions worldwide. These achievements solidify Sumitomo Dainippon Pharma Co Ltd's position as a leading pharmaceutical company focused on improving the lives of patients through innovative treatments and transformative healthcare solutions.

Sumitomo Dainippon Pharma Co Ltd is a renowned pharmaceutical company with a rich history and background. Founded in 1897, it has evolved into a global leader in the healthcare industry. Sumitomo Dainippon Pharma focuses on the research, development, and commercialization of innovative pharmaceuticals across therapeutic areas such as neuroscience, oncology, and rare diseases. The company's commitment to improving patient outcomes and addressing unmet medical needs has driven its success. With a strong emphasis on scientific advancements and strategic collaborations, Sumitomo Dainippon Pharma continues to make significant contributions to the global pharmaceutical landscape.

The main competitors of Sumitomo Dainippon Pharma Co Ltd in the market include Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., and Daiichi Sankyo Company, Limited.

Sumitomo Dainippon Pharma Co Ltd is primarily active in the pharmaceutical industry.

The business model of Sumitomo Dainippon Pharma Co Ltd revolves around the development, manufacturing, and commercialization of innovative pharmaceutical products. As a leading Japanese pharmaceutical company, Sumitomo Dainippon Pharma focuses on researching and providing solutions to significant unmet medical needs. By leveraging its expertise in various therapeutic areas, the company aims to improve patients' health and well-being while contributing to society. Sumitomo Dainippon Pharma actively collaborates with partners, both domestically and internationally, to enhance its global presence and deliver effective and safe treatments to a diverse range of patients.

De Sumitomo Pharma Co K/W is -0,48.

De Sumitomo Pharma Co KUV is 0,48.

De AlleAktien Kwaliteitsscore voor Sumitomo Pharma Co is 2/10.

De Sumitomo Pharma Co omzet is 314,56 mld. JPY.

De Sumitomo Pharma Co winst is -314,97 mld. JPY.

Sumitomo Dainippon Pharma Co Ltd is a well-known Japanese pharmaceutical company that has been in existence since 1896 and is headquartered in Osaka. The company operates in many fields, including mental health, cancer, diabetes, and psychiatric disorders. The main business of Sumitomo Dainippon Pharma is drug development, manufacturing, and marketing. The company offers a wide range of products in various medical specialties, including flagship products such as "Cablivi," an innovative medication for the treatment of thrombotic thrombocytopenic purpura (TTP), and "Latuda," a medication used for the treatment of schizophrenia and bipolar disorders. Sumitomo Dainippon Pharma is also involved in the generic industry. Generics are imitations of brand-name drugs and usually have the same active ingredient content as the original product but are less expensive. The company offers a wide range of generics to meet the needs of patients worldwide. The company also covers the manufacturing and sale of diagnostic systems for clinical practice. The company also conducts preclinical and clinical trials for new drugs, including Holland chamber studies and phase I-IV studies for new drug developments to evaluate their safety and efficacy. In addition, Sumitomo Dainippon Pharma has integrated medical technology, also known as medical devices. The company invests in creative research to develop innovative medical devices that improve the quality of patients' health worldwide. These include diagnostic devices, medical devices, insulin cooling devices, and other medical devices. The company is also involved in the production and sale of cosmetic products, mainly including anti-aging products, skincare products, and makeup products. Several mergers and acquisitions have helped Sumitomo Dainippon Pharma expand its business into various areas in recent years. In 2010, the company expanded into the field of cancer research through the acquisition of Boston Biomedical. A year later, the company acquired Irish company Shionogi & Co Ltd. and entered the business of pharmaceuticals for psychiatric disorders. In 2018, Sumitomo Dainippon Pharma acquired Latin American company Companhia Brasileira de Distribuição Remedios and Midatech Pharma PLC, a company specialized in the development of drugs for rare and life-threatening diseases. Overall, the business model of Sumitomo Dainippon Pharma is very comprehensive and aims to provide a wide range of medical products and services to improve patients' lives. The company is committed to achieving growth and expansion through innovative research and development of new products, as well as through acquisitions and mergers.

Sumitomo Pharma Co keert een dividend van 28,00 JPY uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Sumitomo Pharma Co of het bedrijf keert geen dividend uit.

De ISIN van Sumitomo Pharma Co is JP3495000006.

Het WKN van Sumitomo Pharma Co is 858257.

De ticker van Sumitomo Pharma Co is 4506.T.

Binnen de laatste 12 maanden betaalde Sumitomo Pharma Co een dividend van 14,00 JPY . Dit komt overeen met een dividendrendement van ongeveer 3,70 %. Voor de komende 12 maanden zal Sumitomo Pharma Co naar verwachting een dividend van 14,00 JPY betalen.

De dividendrendement van Sumitomo Pharma Co is momenteel 3,70 %.

Sumitomo Pharma Co betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden oktober, april, oktober, april.

Sumitomo Pharma Co betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 14,00 JPY verwacht. Dit komt overeen met een dividendrendement van 3,67 %.

Sumitomo Pharma Co wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Sumitomo Pharma Co van 1-6-2023 ter hoogte van 7 JPY te ontvangen, moest je het aandeel voor de ex-datum op 30-3-2023 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 1-6-2023.

In het jaar 2023 heeft Sumitomo Pharma Co 28 JPY aan dividenden uitgekeerd.

De dividenden van Sumitomo Pharma Co worden in JPY uitgekeerd.